{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:10:20Z","timestamp":1791414620572,"version":"4.3.3"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1038\/tpj.2013.25","type":"journal-article","created":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T09:56:59Z","timestamp":1373968619000},"page":"389-395","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency"],"prefix":"10.1038","volume":"13","author":[{"given":"M C","family":"van Staveren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Jan Guchelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A B P","family":"van Kuilenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J G","family":"Maring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,7,16]]},"reference":[{"key":"BFtpj201325_CR1","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2165\/00003088-198916040-00002","volume":"16","author":"RB Diasio","year":"1989","unstructured":"Diasio RB, Harris BE . Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989; 16: 215\u2013237.","journal-title":"Clin Pharmacokinet"},{"key":"BFtpj201325_CR2","first-page":"2899","volume":"52","author":"RA Fleming","year":"1992","unstructured":"Fleming RA, Milano G, Thyss A, Etienne MC, Renee N, Schneider M et al. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 1992; 52: 2899\u20132902.","journal-title":"Cancer Res"},{"key":"BFtpj201325_CR3","first-page":"197","volume":"50","author":"BE Harris","year":"1990","unstructured":"Harris BE, Song R, Soong SJ, Diasio RB . Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990; 50: 197\u2013201.","journal-title":"Cancer Res"},{"key":"BFtpj201325_CR4","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1200\/JCO.1994.12.11.2248","volume":"12","author":"MC Etienne","year":"1994","unstructured":"Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renee N et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994; 12: 2248\u20132253.","journal-title":"J Clin Oncol"},{"key":"BFtpj201325_CR5","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/ijc.10599","volume":"101","author":"AB van Kuilenburg","year":"2002","unstructured":"van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH . Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g&gt;a mutation. Int J Cancer 2002; 101: 253\u2013258.","journal-title":"Int J Cancer"},{"key":"BFtpj201325_CR6","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s00280-005-0139-8","volume":"58","author":"J Ciccolini","year":"2006","unstructured":"Ciccolini J, Mercier C, Dahan L, Evrard A, Boyer JC, Richard K et al. Toxic death-case after capecitabine+oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency. Cancer Chemother Pharmacol 2006; 58: 272\u2013275.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFtpj201325_CR7","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/sj.bjc.6600208","volume":"86","author":"JG Maring","year":"2002","unstructured":"Maring JG, van Kuilenburg AB, Haasjes J, Piersma H, Groen HJ, Uges DR et al. Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. Br J Cancer 2002; 86: 1028\u20131033.","journal-title":"Br J Cancer"},{"key":"BFtpj201325_CR8","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/BF03257473","volume":"51","author":"AB van Kuilenburg","year":"2012","unstructured":"van Kuilenburg AB, Hausler P, Schalhorn A, Tanck MW, Proost JH, Terborg C et al. Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G&gt;A mutation in DPYD by means of a Bayesian limited sampling strategy. Clin Pharmacokinet 2012; 51: 163\u2013174.","journal-title":"Clin Pharmacokinet"},{"key":"BFtpj201325_CR9","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.tips.2007.09.009","volume":"28","author":"C Mercier","year":"2007","unstructured":"Mercier C, Ciccolini J . Severe or lethal toxicities upon capecitabine intake: is DPYD genetic polymorphism the ideal culprit? Trends Pharmacol Sci 2007; 28: 597\u2013598.","journal-title":"Trends Pharmacol Sci"},{"key":"BFtpj201325_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00280-010-1282-4","volume":"67","author":"CG Yang","year":"2011","unstructured":"Yang CG, Ciccolini J, Blesius A, Dahan L, Bagarry-Liegey D, Brunet C et al. DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity. Cancer Chemother Pharmacol 2011; 67: 49\u201356.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFtpj201325_CR11","first-page":"1149","volume":"7","author":"AB van Kuilenburg","year":"2001","unstructured":"van Kuilenburg AB, Muller EW, Haasjes J, Meinsma R, Zoetekouw L, Waterham HR et al. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G&gt;A mutation causing DPD deficiency. Clin Cancer Res 2001; 7: 1149\u20131153.","journal-title":"Clin Cancer Res"},{"key":"BFtpj201325_CR12","first-page":"325","volume":"4","author":"Z Lu","year":"1998","unstructured":"Lu Z, Zhang R, Carpenter JT, Diasio RB . Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy. Clin Cancer Res 1998; 4: 325\u2013329.","journal-title":"Clin Cancer Res"},{"key":"BFtpj201325_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.canlet.2006.09.006","volume":"249","author":"M Boisdron-Celle","year":"2007","unstructured":"Boisdron-Celle M, Remaud G, Traore S, Poirier AL, Gamelin L, Morel A et al. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett 2007; 249: 271\u2013282.","journal-title":"Cancer Lett"},{"key":"BFtpj201325_CR14","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1080\/15257770600894576","volume":"25","author":"AB van Kuilenburg","year":"2006","unstructured":"van Kuilenburg AB, van Lenthe H, Van Gennip AH . Activity of pyrimidine degradation enzymes in normal tissues. Nucleosides Nucleotides Nucleic Acids 2006; 25: 1211\u20131214.","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"BFtpj201325_CR15","first-page":"5405","volume":"45","author":"FN Naguib","year":"1985","unstructured":"Naguib FN, el Kouni MH, Cha S . Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 1985; 45: 5405\u20135412.","journal-title":"Cancer Res"},{"key":"BFtpj201325_CR16","first-page":"5433","volume":"53","author":"Z Lu","year":"1993","unstructured":"Lu Z, Zhang R, Diasio RB . Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 1993; 53: 5433\u20135438.","journal-title":"Cancer Res"},{"key":"BFtpj201325_CR17","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1373\/clinchem.2006.074096","volume":"53","author":"AB van Kuilenburg","year":"2007","unstructured":"van Kuilenburg AB, van LH, Zoetekouw L, Kulik W . HPLC-electrospray tandem mass spectrometry for rapid determination of dihydropyrimidine dehydrogenase activity. Clin Chem 2007; 53: 528\u2013530.","journal-title":"Clin Chem"},{"key":"BFtpj201325_CR18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/clinchem\/46.1.9","volume":"46","author":"AB van Kuilenburg","year":"2000","unstructured":"van Kuilenburg AB, van LH, Tromp A, Veltman PC, Van Gennip AH . Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency. Clin Chem 2000; 46: 9\u201317.","journal-title":"Clin Chem"},{"key":"BFtpj201325_CR19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0378-4347(97)00253-3","volume":"696","author":"MR Johnson","year":"1997","unstructured":"Johnson MR, Yan J, Shao L, Albin N, Diasio RB . Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity. J Chromatogr B Biomed Sci Appl 1997; 696: 183\u2013191.","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"BFtpj201325_CR20","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s101470050061","volume":"4","author":"K Dobashi","year":"1999","unstructured":"Dobashi K, Ohe E, Yamaguchi K, Takeshita S, Ayabe T, Miyazaki M et al. Severe 5-fluorouracil-induced toxicity due to increased dihydropyrimidine dehydrogenase activity: report of a patient survival and urinary pyrimidine and dihydropyrimidine levels. Int J Clin Oncol 1999; 4: 241\u2013243.","journal-title":"Int J Clin Oncol"},{"key":"BFtpj201325_CR21","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1097\/FTD.0b013e3181ae4516","volume":"31","author":"AM Lostia","year":"2009","unstructured":"Lostia AM, Lionetto L, Ialongo C, Gentile G, Viterbo A, Malaguti P et al. A liquid chromatography-tandem mass spectrometry method for the determination of 5-Fluorouracil degradation rate by intact peripheral blood mononuclear cells. Ther Drug Monit 2009; 31: 482\u2013488.","journal-title":"Ther Drug Monit"},{"key":"BFtpj201325_CR22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0009-9120(02)00303-X","volume":"35","author":"LK Liem","year":"2002","unstructured":"Liem LK, Choong LH, Woo KT . Porous graphitic carbon shows promise for the rapid screening partial DPD deficiency in lymphocyte dihydropyrimidine dehydrogenase in Chinese, Indian and Malay in Singapore by using semi-automated HPLC-radioassay. Clin Biochem 2002; 35: 181\u2013187.","journal-title":"Clin Biochem"},{"key":"BFtpj201325_CR23","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1023\/A:1012294617392","volume":"12","author":"PA Di","year":"2001","unstructured":"Di PA, Danesi R, Falcone A, Cionini L, Vannozzi F, Masi G et al. Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. Ann Oncol 2001; 12: 1301\u20131306.","journal-title":"Ann Oncol"},{"key":"BFtpj201325_CR24","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1158\/1078-0432.CCR-03-0374","volume":"10","author":"LK Mattison","year":"2004","unstructured":"Mattison LK, Ezzeldin H, Carpenter M, Modak A, Johnson MR, Diasio RB . Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test. Clin Cancer Res 2004; 10: 2652\u20132658.","journal-title":"Clin Cancer Res"},{"key":"BFtpj201325_CR25","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1158\/1078-0432.CCR-05-2020","volume":"12","author":"LK Mattison","year":"2006","unstructured":"Mattison LK, Fourie J, Hirao Y, Koga T, Desmond RA, King JR et al. The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil. Clin Cancer Res 2006; 12: 549\u2013555.","journal-title":"Clin Cancer Res"},{"key":"BFtpj201325_CR26","doi-asserted-by":"publisher","first-page":"5491","DOI":"10.1158\/1078-0432.CCR-06-0747","volume":"12","author":"LK Mattison","year":"2006","unstructured":"Mattison LK, Fourie J, Desmond RA, Modak A, Saif MW, Diasio RB . Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res 2006; 12: 5491\u20135495.","journal-title":"Clin Cancer Res"},{"key":"BFtpj201325_CR27","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1007\/s00280-011-1661-5","volume":"68","author":"MC van Staveren","year":"2011","unstructured":"van Staveren MC, Theeuwes-Oonk B, Guchelaar HJ, van Kuilenburg AB, Maring JG . Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency. Cancer Chemother Pharmacol 2011; 68: 1611\u20131617.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFtpj201325_CR28","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1097\/01.ftd.0000245771.82720.c7","volume":"28","author":"J Ciccolini","year":"2006","unstructured":"Ciccolini J, Mercier C, Evrard A, Dahan L, Boyer JC, Duffaud F et al. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. Ther Drug Monit 2006; 28: 678\u2013685.","journal-title":"Ther Drug Monit"},{"key":"BFtpj201325_CR29","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0378-4347(99)00528-9","volume":"738","author":"D Bi","year":"2000","unstructured":"Bi D, Anderson LW, Shapiro J, Shapiro A, Grem JL, Takimoto CH . Measurement of plasma uracil using gas chromatography-mass spectrometry in normal individuals and in patients receiving inhibitors of dihydropyrimidine dehydrogenase. J Chromatogr B Biomed Sci Appl 2000; 738: 249\u2013258.","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"BFtpj201325_CR30","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.patbio.2008.05.001","volume":"57","author":"FR Ben","year":"2009","unstructured":"Ben FR, Gross E, Ben AS, Hassine H, Saguem S . The dihydrouracil\/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil. Pathol Biol (Paris) 2009; 57: 470\u2013476.","journal-title":"Pathol Biol (Paris)"},{"key":"BFtpj201325_CR31","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j.1365-2710.2004.00569.x","volume":"29","author":"J Ciccolini","year":"2004","unstructured":"Ciccolini J, Mercier C, Blachon MF, Favre R, Durand A, Lacarelle B . A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity. J Clin Pharm Ther 2004; 29: 307\u2013315.","journal-title":"J Clin Pharm Ther"},{"key":"BFtpj201325_CR32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1159\/000099984","volume":"53","author":"ZW Zhou","year":"2007","unstructured":"Zhou ZW, Wang GQ, Wan dS, Lu ZH, Chen YB, Li S et al. The dihydrouracil\/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients. Chemotherapy 2007; 53: 127\u2013131.","journal-title":"Chemotherapy"},{"key":"BFtpj201325_CR33","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1200\/JCO.1999.17.4.1105","volume":"17","author":"E Gamelin","year":"1999","unstructured":"Gamelin E, Boisdron-Celle M, Guerin-Meyer V, Delva R, Lortholary A, Genevieve F et al. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol 1999; 17: 1105.","journal-title":"J Clin Oncol"},{"key":"BFtpj201325_CR34","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1570-0232(02)00239-8","volume":"774","author":"MB Garg","year":"2002","unstructured":"Garg MB, Sevester JC, Sakoff JA, Ackland SP . Simple liquid chromatographic method for the determination of uracil and dihydrouracil plasma levels: a potential pretreatment predictor of 5-fluorouracil toxicity. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 774: 223\u2013230.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"BFtpj201325_CR35","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/0378-4347(95)00228-B","volume":"672","author":"S Sumi","year":"1995","unstructured":"Sumi S, Kidouchi K, Ohba S, Wada Y . Automated screening system for purine and pyrimidine metabolism disorders using high-performance liquid chromatography. J Chromatogr B Biomed Appl 1995; 672: 233\u2013239.","journal-title":"J Chromatogr B Biomed Appl"},{"key":"BFtpj201325_CR36","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jchromb.2005.05.044","volume":"823","author":"G Remaud","year":"2005","unstructured":"Remaud G, Boisdron-Celle M, Hameline C, Morel A, Gamelin E . An accurate dihydrouracil\/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practice. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 823: 98\u2013107.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"BFtpj201325_CR37","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1177\/147323001003800413","volume":"38","author":"MH Kristensen","year":"2010","unstructured":"Kristensen MH, Pedersen P, Mejer J . The value of dihydrouracil\/uracil plasma ratios in predicting 5-fluorouracil-related toxicity in colorectal cancer patients. J Int Med Res 2010; 38: 1313\u20131323.","journal-title":"J Int Med Res"},{"key":"BFtpj201325_CR38","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/sj.bjp.0705651","volume":"141","author":"H Jiang","year":"2004","unstructured":"Jiang H, Lu J, Ji J . Circadian rhythm of dihydrouracil\/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels. Br J Pharmacol 2004; 141: 616\u2013623.","journal-title":"Br J Pharmacol"},{"key":"BFtpj201325_CR39","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/01.ftd.0000162016.11148.1b","volume":"27","author":"PA Di","year":"2005","unstructured":"Di PA, Danesi R, Ciofi L, Vannozzi F, Bocci G, Lastella M et al. Improved analysis of 5-Fluorouracil and 5,6-dihydro-5-Fluorouracil by HPLC with diode array detection for determination of cellular dihydropyrimidine dehydrogenase activity and pharmacokinetic profiling. Ther Drug Monit 2005; 27: 362\u2013368.","journal-title":"Ther Drug Monit"},{"key":"BFtpj201325_CR40","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0378-4347(01)00359-0","volume":"762","author":"R Deporte-Fety","year":"2001","unstructured":"Deporte-Fety R, Picot M, Amiand M, Moreau A, Campion L, Lanoe D et al. High-performance liquid chromatographic assay with ultraviolet detection for quantification of dihydrofluorouracil in human lymphocytes: application to measurement of dihydropyrimidine dehydrogenase activity. J Chromatogr B Biomed Sci Appl 2001; 762: 203\u2013209.","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"BFtpj201325_CR41","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jchromb.2005.07.023","volume":"824","author":"G Remaud","year":"2005","unstructured":"Remaud G, Boisdron-Celle M, Morel A, Gamelin A . Sensitive MS\/MS-liquid chromatography assay for simultaneous determination of tegafur, 5-fluorouracil and 5-fluorodihydrouracil in plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 824: 153\u2013160.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"BFtpj201325_CR42","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1097\/FTD.0b013e3181b9b8c0","volume":"31","author":"JH Beumer","year":"2009","unstructured":"Beumer JH, Boisdron-Celle M, Clarke W, Courtney JB, Egorin MJ, Gamelin E et al. Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer. Ther Drug Monit 2009; 31: 688\u2013694.","journal-title":"Ther Drug Monit"},{"key":"BFtpj201325_CR43","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.clpt.2006.06.007","volume":"80","author":"G Bocci","year":"2006","unstructured":"Bocci G, Barbara C, Vannozzi F, Di PA, Melosi A, Barsanti G et al. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. Clin Pharmacol Ther 2006; 80: 384\u2013395.","journal-title":"Clin Pharmacol Ther"},{"key":"BFtpj201325_CR44","first-page":"3032","volume":"6","author":"G Bocci","year":"2000","unstructured":"Bocci G, Danesi R, Di Paolo AD, Innocenti F, Allegrini G, Falcone A et al. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. Clin Cancer Res 2000; 6: 3032\u20133037.","journal-title":"Clin Cancer Res"},{"key":"BFtpj201325_CR45","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1067\/mcp.2002.128867","volume":"72","author":"PA Di","year":"2002","unstructured":"Di PA, Danesi R, Vannozzi F, Falcone A, Mini E, Cionini L et al. Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer. Clin Pharmacol Ther 2002; 72: 627\u2013637.","journal-title":"Clin Pharmacol Ther"},{"key":"BFtpj201325_CR46","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1080\/15257770802145009","volume":"27","author":"AB van Kuilenburg","year":"2008","unstructured":"van Kuilenburg AB, Maring JG, Schalhorn A, Terborg C, Schmalenberg H, Behnke D et al. Pharmacokinetics of 5-fluorouracil in patients heterozygous for the IVS14+1 G&gt;A mutation in the dihydropyrimidine dehydrogenase gene. Nucleosides Nucleotides Nucleic Acids 2008; 27: 692\u2013698.","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"BFtpj201325_CR47","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1006\/abio.2002.5666","volume":"306","author":"H Ezzeldin","year":"2002","unstructured":"Ezzeldin H, Okamoto Y, Johnson MR, Diasio RB . A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency. Anal Biochem 2002; 306: 63\u201373.","journal-title":"Anal Biochem"},{"key":"BFtpj201325_CR48","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1089\/109065703322146777","volume":"7","author":"J Fischer","year":"2003","unstructured":"Fischer J, Schwab M, Eichelbaum M, Zanger UM . Mutational analysis of the human dihydropyrimidine dehydrogenase gene by denaturing high-performance liquid chromatography. Genet Test 2003; 7: 97\u2013105.","journal-title":"Genet Test"},{"key":"BFtpj201325_CR49","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/humu.9201","volume":"22","author":"E Gross","year":"2003","unstructured":"Gross E, Ullrich T, Seck K, Mueller V, de Wit WM, von Schilling SC et al. Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects. Hum Mutat 2003; 22: 498.","journal-title":"Hum Mutat"},{"key":"BFtpj201325_CR50","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1042\/bj3640157","volume":"364","author":"AB van Kuilenburg","year":"2002","unstructured":"van Kuilenburg AB, Dobritzsch D, Meinsma R, Haasjes J, Waterham HR, Nowaczyk MJ et al. Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure. Biochem J 2002; 364: 157\u2013163.","journal-title":"Biochem J"},{"key":"BFtpj201325_CR51","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.clinbiochem.2011.03.033","volume":"44","author":"S Weidensee","year":"2011","unstructured":"Weidensee S, Goettig P, Bertone M, Haas D, Magdolen V, Kiechle M et al. A mild phenotype of dihydropyrimidine dehydrogenase deficiency and developmental retardation associated with a missense mutation affecting cofactor binding. Clin Biochem 2011; 44: 722\u2013724.","journal-title":"Clin Biochem"},{"key":"BFtpj201325_CR52","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1373\/49.10.1661","volume":"49","author":"R Ahluwalia","year":"2003","unstructured":"Ahluwalia R, Freimuth R, McLeod HL, Marsh S . Use of pyrosequencing to detect clinically relevant polymorphisms in dihydropyrimidine dehydrogenase. Clin Chem 2003; 49: 1661\u20131664.","journal-title":"Clin Chem"},{"key":"BFtpj201325_CR53","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2217\/pgs.09.28","volume":"10","author":"U Amstutz","year":"2009","unstructured":"Amstutz U, Farese S, Aebi S, Largiader CR . Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. Pharmacogenomics 2009; 10: 931\u2013944.","journal-title":"Pharmacogenomics"},{"key":"BFtpj201325_CR54","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1158\/1535-7163.MCT-06-0327","volume":"5","author":"A Morel","year":"2006","unstructured":"Morel A, Boisdron-Celle M, Fey L, Soulie P, Craipeau MC, Traore S et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther 2006; 5: 2895\u20132904.","journal-title":"Mol Cancer Ther"},{"key":"BFtpj201325_CR55","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0009-9120(01)00188-6","volume":"34","author":"M Nauck","year":"2001","unstructured":"Nauck M, Gierens H, Marz W, Wieland H . Rapid detection of a common dihydropyrimidine dehydrogenase mutation associated with 5-fluorouracil toxicity and congenital thymine uraciluria using fluorogenic hybridization probes. Clin Biochem 2001; 34: 103\u2013105.","journal-title":"Clin Biochem"},{"key":"BFtpj201325_CR56","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/01.GIM.0000118061.66602.A5","volume":"6","author":"N Salgueiro","year":"2004","unstructured":"Salgueiro N, Veiga I, Fragoso M, Sousa O, Costa N, Pellon ML et al. Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-fluorouracil toxicity in Portuguese colorectal cancer patients. Genet Med 2004; 6: 102\u2013107.","journal-title":"Genet Med"},{"key":"BFtpj201325_CR57","first-page":"4705","volume":"6","author":"AB van Kuilenburg","year":"2000","unstructured":"van Kuilenburg AB, Haasjes J, Richel DJ, Zoetekouw L, van LH, De Abreu RA et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 2000; 6: 4705\u20134712.","journal-title":"Clin Cancer Res"},{"key":"BFtpj201325_CR58","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1158\/1078-0432.CCR-10-2209","volume":"17","author":"MJ Deenen","year":"2011","unstructured":"Deenen MJ, Tol J, Burylo AM, Doodeman VD, de Boer A, Vincent A et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res 2011; 17: 3455\u20133468.","journal-title":"Clin Cancer Res"},{"key":"BFtpj201325_CR59","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00439-010-0879-3","volume":"128","author":"AB van Kuilenburg","year":"2010","unstructured":"van Kuilenburg AB, Meijer J, Mul AN, Meinsma R, Schmid V, Dobritzsch D et al. Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity. Hum Genet 2010; 128: 529\u2013538.","journal-title":"Hum Genet"},{"key":"BFtpj201325_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/PL00008711","volume":"104","author":"AB van Kuilenburg","year":"1999","unstructured":"van Kuilenburg AB, Vreken P, Abeling NG, Bakker HD, Meinsma R, van LH et al. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet 1999; 104: 1\u20139.","journal-title":"Hum Genet"},{"key":"BFtpj201325_CR61","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s00280-011-1709-6","volume":"68","author":"E Giorgio","year":"2011","unstructured":"Giorgio E, Caroti C, Mattioli F, Uliana V, Parodi MI, D'Amico M et al. Severe fluoropyrimidine-related toxicity: clinical implications of DPYD analysis and UH2\/U ratio evaluation. Cancer Chemother Pharmacol 2011; 68: 1355\u20131361.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFtpj201325_CR62","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1365-2125.2007.02869.x","volume":"64","author":"N Magne","year":"2007","unstructured":"Magne N, Etienne-Grimaldi MC, Cals L, Renee N, Formento JL, Francoual M et al. Dihydropyrimidine dehydrogenase activity and the IVS14+1G&gt;A mutation in patients developing 5FU-related toxicity. Br J Clin Pharmacol 2007; 64: 237\u2013240.","journal-title":"Br J Clin Pharmacol"},{"key":"BFtpj201325_CR63","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s10528-007-9109-7","volume":"45","author":"Y Okamoto","year":"2007","unstructured":"Okamoto Y, Ueta A, Sumi S, Ito T, Okubo Y, Jose Y et al. SSCP screening of the dihydropyrimidine dehydrogenase gene polymorphisms of the Japanese population using a semi-automated electrophoresis unit. Biochem Genet 2007; 45: 713\u2013724.","journal-title":"Biochem Genet"},{"key":"BFtpj201325_CR64","doi-asserted-by":"publisher","first-page":"8699","DOI":"10.1158\/1078-0432.CCR-05-1520","volume":"11","author":"HH Ezzeldin","year":"2005","unstructured":"Ezzeldin HH, Lee AM, Mattison LK, Diasio RB . Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin Cancer Res 2005; 11: 8699\u20138705.","journal-title":"Clin Cancer Res"},{"key":"BFtpj201325_CR65","doi-asserted-by":"publisher","first-page":"7100","DOI":"10.1158\/1078-0432.CCR-04-0337","volume":"10","author":"T Noguchi","year":"2004","unstructured":"Noguchi T, Tanimoto K, Shimokuni T, Ukon K, Tsujimoto H, Fukushima M et al. Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells. Clin Cancer Res 2004; 10: 7100\u20137107.","journal-title":"Clin Cancer Res"},{"key":"BFtpj201325_CR66","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1756-9966-27-54","volume":"27","author":"U Amstutz","year":"2008","unstructured":"Amstutz U, Farese S, Aebi S, Largiader CR . Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy. J Exp Clin Cancer Res 2008; 27: 54.","journal-title":"J Exp Clin Cancer Res"},{"key":"BFtpj201325_CR67","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1186\/1471-2407-10-470","volume":"10","author":"J Savva-Bordalo","year":"2010","unstructured":"Savva-Bordalo J, Ramalho-Carvalho J, Pinheiro M, Costa VL, Rodrigues A, Dias PC et al. Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients. BMC Cancer 2010; 10: 470.","journal-title":"BMC Cancer"},{"key":"BFtpj201325_CR68","first-page":"2832","volume":"7","author":"M Raida","year":"2001","unstructured":"Raida M, Schwabe W, Hausler P, van Kuilenburg AB, Van Gennip AH, Behnke D et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5\u2032-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. Clin Cancer Res 2001; 7: 2832\u20132839.","journal-title":"Clin Cancer Res"},{"key":"BFtpj201325_CR69","doi-asserted-by":"publisher","first-page":"5886","DOI":"10.1158\/1078-0432.CCR-04-1784","volume":"11","author":"K Seck","year":"2005","unstructured":"Seck K, Riemer S, Kates R, Ullrich T, Lutz V, Harbeck N et al. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals. Clin Cancer Res 2005; 11: 5886\u20135892.","journal-title":"Clin Cancer Res"},{"key":"BFtpj201325_CR70","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1006\/abio.1999.4461","volume":"278","author":"MR Johnson","year":"2000","unstructured":"Johnson MR, Wang K, Smith JB, Heslin MJ, Diasio RB . Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal Biochem 2000; 278: 175\u2013184.","journal-title":"Anal Biochem"},{"key":"BFtpj201325_CR71","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/00008571-200210000-00007","volume":"12","author":"AB van Kuilenburg","year":"2002","unstructured":"van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH . High prevalence of the IVS14+1G&gt;A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 2002; 12: 555\u2013558.","journal-title":"Pharmacogenetics"},{"key":"BFtpj201325_CR72","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1200\/JCO.2006.10.4182","volume":"26","author":"M Schwab","year":"2008","unstructured":"Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, Dippon J et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 2008; 26: 2131\u20132138.","journal-title":"J Clin Oncol"},{"key":"BFtpj201325_CR73","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/(SICI)1097-0142(19960201)77:3<441::AID-CNCR4>3.0.CO;2-N","volume":"77","author":"EC Gamelin","year":"1996","unstructured":"Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, Maillart PJ, Goudier MJ, Burtin PC et al. Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 1996; 77: 441\u2013451.","journal-title":"Cancer"},{"key":"BFtpj201325_CR74","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/sj.bjc.6690097","volume":"79","author":"AB van Kuilenburg","year":"1999","unstructured":"van Kuilenburg AB, van LH, Blom MJ, Mul EP, Van Gennip AH . Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients. Br J Cancer 1999; 79: 620\u2013626.","journal-title":"Br J Cancer"}],"updated-by":[{"DOI":"10.1038\/tpj.2014.25","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2014,7,24]],"date-time":"2014-07-24T00:00:00Z","timestamp":1406160000000}}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/tpj201325.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201325","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201325.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T10:35:40Z","timestamp":1647945340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tpj201325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,16]]},"references-count":74,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["BFtpj201325"],"URL":"https:\/\/doi.org\/10.1038\/tpj.2013.25","relation":{"erratum":[{"id-type":"doi","id":"10.1038\/tpj.2014.25","asserted-by":"object"}]},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,16]]},"assertion":[{"value":"7 November 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}